Less than half of Montana students demonstrated proficiency or above in math and language arts on recent state assessments, ...
Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today presented clinical data for CTD402, its investigational allogeneic anti-CD7 CAR ...
Cancer Research UK's Centre for Drug Development is sponsoring and conducting the phase I/II clinical trial of ALETA-001, the lead agent in Aleta Biotherapeutics' portfolio. Additional clinical trial ...
By the end of 3 induction cycles, the best minimal residual disease (MRD) negativity rate and the MRD-negative complete ...
Dramatically improved disease control with 21.2 months vs. 2.9 months median event-free survival (EFS) Favorablesafety ...
Clinical data from investigator-initiated trials in 20 patients with multiple autoimmune diseases show allogeneic CAR-T QT-019B was generally well tolerated and demonstrated encouraging efficacy –– QT ...
Lunsumio in combination with lenalidomide may offer an effective treatment in relapsed or refractory follicular lymphoma based on first data from single-arm cohort of Phase III CELESTIMO study –– Data ...
Molecular responses continue to deepen with extended treatment duration, reaching 60% major molecular response at 21 cycles ...
Peak assays of 465 g/t Ag & 20.2 g/t Au infill high-grade target area HIGHLIGHTS New Tolmer diamond drilling assays confirm local structural model analogous to eastern portion of historical Tarcoola ...
Range Resources Corporation (RRC) attracted attention following a downgrade to “Underweight” from JP Morgan’s analyst Arun Jayaram. This rating change suggests a cautious outlook on the stock, which ...
In a recent development that may cause ripples in the electric vehicle market, Morgan Stanley analyst Adam Jonas downgraded Rivian Automotive, Inc. (RIVN) to an “Underweight” rating o 8, 2025. The new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback